Table 3. Regular formoterol v placebo trial details.
| Duration (weeks) | % children on ICS background Rx | Formoterol 48 mcg/day (N) | Formoterol 24 mcg/day (N) | Formoterol 12 mcg/day (N) | Placebo (N) | Brand | Age Ranges | |
|---|---|---|---|---|---|---|---|---|
| Bensch 2002 | 52 | 69 | 171 | 171 | 176 | Foradil | 5 to 12 | |
| Corren 2007 | 12 | 0 | 9 | 9 | Oxis | 6 to 11 | ||
| Levy 2005 | 12 | 72 | 127 | 122 | Foradil | 5 to 13 | ||
| Von Berg 2003 | 12 | 82 | 83 | 81 | 84 | Oxis | 6 to 17 | |
| Zimmerman 2004 | 12 | 100 | 94 | 105 | 101 | Oxis | 6 to 11 | |
| Total | mean = 27 weeks | 171 | 475 | 186 | 492 |
All trials were sponsored by AstraZeneca or Novartis, and contributed data on all-cause mortality and non-fatal serious adverse events, except Levy 2005 for which mortality data was not available